{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:07:31Z","timestamp":1763510851842,"version":"3.45.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Ratchadapiseksompotch Research Affairs, Faculty of Medicine, Chulalongkorn University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23569-9","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T15:40:49Z","timestamp":1763134849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Levofloxacin for the prevention of febrile episodes in non-Hodgkin lymphoma patients treated with CHOP plus rituximab in a randomized controlled trial"],"prefix":"10.1038","volume":"15","author":[{"given":"Mutita","family":"Surakijboworn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantana","family":"Polprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ponlapat","family":"Rojnuckarin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-9139","authenticated-orcid":false,"given":"Noppacharn","family":"Uaprasert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"key":"23569_CR1","doi-asserted-by":"publisher","first-page":"e7056","DOI":"10.1002\/cam4.7056","volume":"13","author":"J Huang","year":"2024","unstructured":"Huang, J. et al. Global burden, risk factors, and trends of non-Hodgkin lymphoma: a worldwide analysis of cancer registries. Cancer Med. 13, e7056. https:\/\/doi.org\/10.1002\/cam4.7056 (2024).","journal-title":"Cancer Med."},{"key":"23569_CR2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ajh.24086","volume":"90","author":"M Al-Hamadani","year":"2015","unstructured":"Al-Hamadani, M. et al. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National cancer data base from 1998 to 2011. Am. J. Hematol. 90, 790\u2013795 (2015).","journal-title":"Am. J. Hematol."},{"key":"23569_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/hon.2392","volume":"36","author":"T Intragumtornchai","year":"2018","unstructured":"Intragumtornchai, T. et al. Non-Hodgkin lymphoma in South East asia: an analysis of the histopathology, clinical features, and survival from Thailand. Hematol. Oncol. 36, 28\u201336 (2018).","journal-title":"Hematol. Oncol."},{"key":"23569_CR4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl. J. Med. 346, 235\u2013242 (2002).","journal-title":"N Engl. J. Med."},{"key":"23569_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh, M. et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera international trial (MInT) group. Lancet Oncol. 7, 379\u2013391 (2006).","journal-title":"Lancet Oncol."},{"key":"23569_CR6","first-page":"647","volume":"20","author":"R Pettengell","year":"2012","unstructured":"Pettengell, R. et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer. 20, 647\u2013652 (2012).","journal-title":"Support Care Cancer"},{"key":"23569_CR7","first-page":"571","volume":"28","author":"M Yokoyama","year":"2020","unstructured":"Yokoyama, M. et al. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 28, 571\u2013579 (2020).","journal-title":"Support Care Cancer"},{"key":"23569_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clml.2012.06.004","volume":"12","author":"P Lugtenburg","year":"2012","unstructured":"Lugtenburg, P. et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin. Lymphoma Myeloma Leuk. 12, 297\u2013305 (2012).","journal-title":"Lymphoma Myeloma Leuk."},{"key":"23569_CR9","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3346\/jkms.2014.29.11.1493","volume":"29","author":"YW Choi","year":"2014","unstructured":"Choi, Y. W. et al. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. J. Korean Med. Sci. 29, 1493\u20131500 (2014).","journal-title":"J. Korean Med. Sci."},{"key":"23569_CR10","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1080\/10428194.2016.1265111","volume":"58","author":"VA Morrison","year":"2017","unstructured":"Morrison, V. A. et al. Patterns of growth factor usage and febrile neutropenia among older patients with diffuse large B-cell non-Hodgkin lymphoma treated with CHOP or R-CHOP: the intergroup experience (CALGB 9793; ECOG-SWOG 4494). Leuk. Lymphoma. 58, 1814\u20131822 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"23569_CR11","first-page":"45","volume":"27","author":"J Puchitsathian","year":"2017","unstructured":"Puchitsathian, J. & Rojnuckarin, P. High incidence of febrile neutropenia in non-Hodgkin lymphoma patients receiving CHOP chemotherapy despite G-CSF prophylaxis. J. Hematol. Transfus. Med. 27, 45\u201355 (2017).","journal-title":"J. Hematol. Transfus. Med."},{"key":"23569_CR12","unstructured":"National Comprehensive Cancer Network. Hematopoietic growth factors (Version 1.2023). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf (2023)."},{"key":"23569_CR13","doi-asserted-by":"publisher","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford, J., Caserta, C. & Roila, F. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann. Oncol. 21, v248\u2013v251 (2010).","journal-title":"Ann. Oncol."},{"key":"23569_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","volume":"33","author":"TJ Smith","year":"2015","unstructured":"Smith, T. J. et al. Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J. Clin. Oncol. 33, 3199\u20133212 (2015).","journal-title":"J. Clin. Oncol."},{"key":"23569_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/infdis\/161.3.381","volume":"161","author":"WT Hughes","year":"1990","unstructured":"Hughes, W. T. et al. From the infectious diseases society of america: guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J. Infect. Dis. 161, 381\u2013396 (1990).","journal-title":"J. Infect. Dis."},{"key":"23569_CR16","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/jac\/44.5.587","volume":"44","author":"KG Kerr","year":"1999","unstructured":"Kerr, K. G. The prophylaxis of bacterial infections in neutropenic patients. J. Antimicrob. Chemother. 44, 587\u2013591 (1999).","journal-title":"J. Antimicrob. Chemother."},{"key":"23569_CR17","doi-asserted-by":"publisher","first-page":"986938","DOI":"10.1155\/2014\/986938","volume":"2014","author":"P Villafuerte-Gutierrez","year":"2014","unstructured":"Villafuerte-Gutierrez, P., Villalon, L., Losa, J. E. & Henriquez-Camacho, C. Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update. Adv. Hematol. 2014, 986938 (2014).","journal-title":"Adv. Hematol."},{"key":"23569_CR18","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz, R. A. et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J. Clin. Oncol. 36, 3043\u20133054 (2018).","journal-title":"J. Clin. Oncol."},{"key":"23569_CR19","unstructured":"National Comprehensive Cancer Network. Prevention and treatment of cancer-related infection (Version 2.2022). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf (2022)."},{"key":"23569_CR20","first-page":"2","volume":"4","author":"CM Rotstein","year":"1997","unstructured":"Rotstein, C. M. & Goldberg, N. Fluoroquinolone prophylaxis for profoundly neutropenic cancer patients: a meta-analysis. Curr. Oncol. 4, 2\u20137 (1997).","journal-title":"Curr. Oncol."},{"key":"23569_CR21","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1200\/JCO.1998.16.3.1179","volume":"16","author":"EA Engels","year":"1998","unstructured":"Engels, E. A., Lau, J. & Barza, M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J. Clin. Oncol. 16, 1179\u20131187 (1998).","journal-title":"J. Clin. Oncol."},{"key":"23569_CR22","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.ejca.2005.03.006","volume":"41","author":"MD Van de Wetering","year":"2005","unstructured":"Van de Wetering, M. D. et al. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomized controlled trials. Eur. J. Cancer. 41, 1372\u20131382 (2005).","journal-title":"Eur. J. Cancer"},{"key":"23569_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve, G. et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl. J. Med. 353, 977\u2013987 (2005).","journal-title":"N Engl. J. Med."},{"key":"23569_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1056\/NEJMoa050078","volume":"353","author":"M Cullen","year":"2005","unstructured":"Cullen, M. et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl. J. Med. 353, 988\u2013998 (2005).","journal-title":"N Engl. J. Med."},{"key":"23569_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/sim.4780010204","volume":"1","author":"LS Freedman","year":"1982","unstructured":"Freedman, L. S. Tables of the number of patients required in clinical trials using the logrank test. Stat. Med. 1, 121\u2013129 (1982).","journal-title":"Stat. Med."},{"key":"23569_CR26","unstructured":"National Antimicrobial Resistance Surveillance Center (Thailand). Antibiogram 2022: Summary from 68 sentinel hospitals. at Ministry of Public Health, https:\/\/narst.dmsc.moph.go.th\/download\/antibiogram_2022.pdf (2023)."},{"key":"23569_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/v13010008","volume":"13","author":"SLP Scroggs","year":"2020","unstructured":"Scroggs, S. L. P. et al. Fluoroquinolone antibiotics exhibit low antiviral activity against SARS-CoV-2 and MERS-CoV. Viruses 13, 8 (2020).","journal-title":"Viruses"},{"key":"23569_CR28","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s43440-021-00282-8","volume":"73","author":"K Marciniec","year":"2021","unstructured":"Marciniec, K., Beberok, A., Boryczka, S. & Wrze\u015bniok, D. The application of in Silico experimental model in the assessment of Ciprofloxacin and Levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular Docking analysis. Pharmacol. Rep. 73, 1765\u20131780 (2021).","journal-title":"Pharmacol. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23569-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23569-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23569-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:04:11Z","timestamp":1763510651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23569-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23569"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23569-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"25 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University (IRB No. 0788\/65) and adhered to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"40020"}}